The BATTLE to Personalize Lung Cancer Prevention Through Reverse Migration

Overview

Journal Cancer Prev Res (Phila)

Specialty Oncology

Date 2011 Jul 8

PMID 21733820

Citations 27

Authors

Kathryn A Gold

Edward S Kim

J Jack Lee

Ignacio I Wistuba

Carol J Farhangfar

Waun Ki Hong

Affiliations

Soon will be listed here.

Abstract

Agents can enter clinical development for cancer prevention either initially or after previous development for a different indication, such as arthritis, with both approaches consuming many years of development before an agent is fully evaluated for cancer prevention. We propose the following, third approach: reverse migration, that is, importing agents, targets, and study designs to personalize interventions and concepts developed in advanced cancer to the setting of cancer prevention. Importing these "ready-made" features from therapy will allow reverse migration to streamline preventive agent development. We recently reported the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial of personalized lung cancer therapy and now propose the reverse migration development of personalized lung cancer prevention based on the BATTLE model.

Citing Articles

Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies.

Arandhara A, Bhuyan P, Das B Discov Oncol. 2025; 16(1):159.

PMID: 39934547 PMC: 11814423. DOI: 10.1007/s12672-025-01902-y.

Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival.

Nishino M, Wang X, Ricciuti B, Tseng S, Park H, Alessi J Eur Radiol. 2023; 33(10):7284-7293.

PMID: 37099174 PMC: 10896107. DOI: 10.1007/s00330-023-09658-1.

Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.

Nishino M, Hong F, Ricciuti B, Hatabu H, Awad M JCO Precis Oncol. 2021; 5.

PMID: 34250409 PMC: 8232801. DOI: 10.1200/PO.20.00478.

A Signature Enrichment Design with Bayesian Adaptive Randomization.

Xia F, George S, Ning J, Li L, Huang X J Appl Stat. 2021; 48(6):1091-1110.

PMID: 34024982 PMC: 8132854. DOI: 10.1080/02664763.2020.1757048.

Kank1 and Ki67 expression are associated with poor prognosis in human pulmonary adenocarcinoma.

Shen X, Ni C, Xu S, Zhan S, Gu G Int J Clin Exp Pathol. 2020; 13(9):2312-2318.

PMID: 33042336 PMC: 7539868.

References

AUERBACH O, STOUT A, HAMMOND E, GARFINKEL L . Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med. 1961; 265:253-67. DOI: 10.1056/NEJM196108102650601. View

Jiralerspong S, Palla S, Giordano S, Meric-Bernstam F, Liedtke C, Barnett C . Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27(20):3297-302. PMC: 2736070. DOI: 10.1200/JCO.2009.19.6410. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Belinsky S, Liechty K, Gentry F, Wolf H, Rogers J, Vu K . Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006; 66(6):3338-44. DOI: 10.1158/0008-5472.CAN-05-3408. View

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Chan A, Sima C, Zauber A, Ridker P, Hawk E, Bertagnolli M . C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011; 4(8):1172-80. PMC: 3151679. DOI: 10.1158/1940-6207.CAPR-10-0403. View

Giardiello F, Hamilton S, KRUSH A, Piantadosi S, Hylind L, Celano P . Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993; 328(18):1313-6. DOI: 10.1056/NEJM199305063281805. View

Penney K, Schumacher F, Li H, Kraft P, Morris J, Kurth T . A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila). 2010; 3(5):604-10. PMC: 2865569. DOI: 10.1158/1940-6207.CAPR-09-0216. View

Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295(23):2727-41. DOI: 10.1001/jama.295.23.joc60074. View

10.

Gadgeel S, Ruckdeschel J, Heath E, Heilbrun L, Venkatramanamoorthy R, Wozniak A . Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007; 2(4):299-305. DOI: 10.1097/01.JTO.0000263712.61697.69. View

11.

Zhou K, Bellenguez C, Spencer C, Bennett A, Coleman R, Tavendale R . Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2010; 43(2):117-20. PMC: 3030919. DOI: 10.1038/ng.735. View

12.

Gandhi L, McNamara K, Li D, Borgman C, McDermott U, Brandstetter K . Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev Res (Phila). 2009; 2(4):330-7. PMC: 2696128. DOI: 10.1158/1940-6207.CAPR-08-0213. View

13.

Memmott R, Dennis P . LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol. 2009; 27(34):e226. DOI: 10.1200/JCO.2009.25.3963. View

14.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

15.

Engelman J, Cantley L . Chemoprevention meets glucose control. Cancer Prev Res (Phila). 2010; 3(9):1049-52. DOI: 10.1158/1940-6207.CAPR-10-0178. View

16.

Blackburn E . Walking the walk from genes through telomere maintenance to cancer risk. Cancer Prev Res (Phila). 2011; 4(4):473-5. DOI: 10.1158/1940-6207.CAPR-11-0066. View

17.

Tsao A, McDonnell T, Lam S, Putnam J, Bekele N, Hong W . Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev. 2003; 12(7):660-4. View

18.

Spitz M, Etzel C, Dong Q, Amos C, Wei Q, Wu X . An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila). 2009; 1(4):250-4. PMC: 2854404. DOI: 10.1158/1940-6207.CAPR-08-0060. View

19.

Lippman S, Hawk E . Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res. 2009; 69(13):5269-84. DOI: 10.1158/0008-5472.CAN-09-1750. View

20.

Hammerman P, Sos M, Ramos A, Xu C, Dutt A, Zhou W . Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2012; 1(1):78-89. PMC: 3274752. DOI: 10.1158/2159-8274.CD-11-0005. View